Charles Skarbek
Synthesis of 6-methylphenanthridines and evaluation against human papillomavirus-related endocervical adenocarcinoma (KB 3.1) cells. H. Maslah, C. Skarbek, R. Labruère, Phytochem. Lett., 2023, 54, 146-152
Re-designing environmentally persistent pharmaceutical pollutant through programmed inactivation: The case of methotrexate. A. Espinosa, E. Rascol, M. A. Flos, C. Skarbek, P. Lieben, E. Bannerman, A. D. Martinez, S. Pethe, P. Benoit, S. Nélieu, R. Labruère, Chemosphere, 2022, 306, 135616
Photodegradation of methotrexate in aqueous solution: degradation kinetics and identification of transformation products. A. Espinosa, S. Nélieu, P. Lieben, C. Skarbek, R. Labruère, P. Benoit, Environ. Sci. Pollut. Res., 2022, 29, 6060-6071
In-cell generation of anticancer phenanthridine through bioorthogonal cyclization: a paradigm in antitumor prodrug development. H. Maslah, C. Skarbek, C. Gourson, M.-A. Plamont, S. Pethe, L. Jullien, T. Le Saux, R. Labruère, Angew. Chem. Int. Ed., 2021, 60, 24043-24047
Structural modification and biological activity studies of Tagitinin C and its derivatives. T. H. Au, C. Skarbek, S. Pethe, R. Labruère, J.-P. Baltaze, T. P. Hoa Nguyen, T. T. H. Vu, G. Vo-Thanh, Tetrahedron, 2021, 92, 132248
Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironment. H. Maslah, C. Skarbek, S. Pethe, R. Labruère, Eur. J. Med. Chem., 2020, 207, 112670
Arylboronate prodrugs of doxorubicin as promising chemotherapy for pancreatic cancer. C. Skarbek, S. Serra, H. Maslah, E. Rascol, R. Labruère, Bioorg. Chem., 2019, 91, 103158